Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
C BucelliIsabella CapodannoM C MiggianoF CavazziniS Leonetti CrescenziS RussoI CarmosinoM AnnunziataFederica SoràM BonifacioL LucianoG CaocciG LoglisciC ElenaF LunghiR MullaiI AttolicoG BinottoE CrisàPaolo SportolettiA Di VeroliA R ScortechiniA P LeporaceA MaggiM CrugnolaF StagnoR SancettaP MurganoD RapezziD LuziD I VincelliS GalimbertiM BocchiaC FavaA MalatoElisabetta AbruzzeseG SaglioG SpecchiaMassimo BrecciaAlessandra IurloMario TiribelliR LatagliataPublished in: European journal of haematology (2024)
IM was in our Centers the preferred frontline therapy for older CP-CML patients, with increasing utilization after the introduction of generic formulations. However, 2G-TKIs are still used in a substantial proportion of patients, suggesting individualized physician assessments regarding patient suitability and expectations. Further investigation is needed to assess efficacy and safety of reduced TKI doses in this patient population.